Working Conference

Classification and Management of Mast Cell Neoplasms in Dogs and Humans: A Comparative Oncology Approach

Vienna, May 17, 2019

Friday, May 17
Aula of the University of Vienna, Old General Hospital of Vienna

8:00 Welcome Coffee

8:15 Welcome Notes
Petra Winter, Rector of the University of Veterinary Medicine Vienna

8:20 Introduction and Background
Michael Willmann and Peter Valent

8:30-10:00 Session I: Mast Cells in Health and Disease
Chair: M. Dacasto and D.M. Vail

8:30 Biology and Roles of Mast Cells – The Beauty & The Beast
Stephen J. Galli (Stanford, CA, USA)

9:00 Mast Cell Activation: Basic Concepts and Clinical Implications
Erika Jensen-Jarolim (Vienna, Austria)

9:20 Mast Cells in Human Neoplastic Diseases
Peter Valent (Vienna, Austria)

9:40 Mast Cells in Canine Neoplastic Diseases
Michael Willmann (Vienna, Austria)

10:00 Coffee Break

10:40-12:20 Session II: Molecular Markers and Targets in Mast Cell Neoplasms
Chairs: L. Marconato and M. Kiupel

10:40 KIT Mutation Analysis in Human Mast Cell Neoplasms
Michel Arock (Paris, France)
11:00  *KIT* Mutation Analysis for Diagnosis and Prognostication in Canine MCT
TBD

11:20  *SRSF2, ASXL1, RUNX1, JAK2* and other ‘Non-*KIT* Mutations’:
Diagnostic and Prognostic Value in Systemic Mastocytosis
Mohamad Jawhar (Mannheim, Germany)

11:40  Mutational *TET2, IDH1, IDH2, SRSF2, SF3B1* and *RAS*:
Are they Detectable and Relevant in Canine MCT?
Mauro Dacasto (Padova, Italy)

12:00  CDK6 as Key Regulator of Leukemic Stem Cells
Veronika Sexl (Vienna, Austria)

12:20  Lunch Buffet

13:30-14:40  Session III: Pathology, Grading and Staging of Mast Cell Neoplasms
Chair: H.-P. Horny and S.J. Galli

13:30  Histopathology and Immunohistochemistry in Mastocytosis: Status 2019
Hans-Peter Horny (Munich, Germany)

14:00  Canine MCT: A Combined Clinical and Pathologic Approach
to Diagnosis and Prognosis
Matti Kiupel (East Lansing, Michigan, USA)

14:20  The Role of the Lymph Node in Canine Mast Cell Tumors
Laura Marconato (Bologna, Italy)

14:40  Coffee Break

15:00-17:00  Session IV: Basic and Translational Research in Human and Canine
Mast Cell Disorders
Chair: E. Hadzijusufovic and M. Müller

15:00  Delineation of Markers and Targets in Neoplastic Stem Cells in ASM and MCL
Gregor Eisenwort (Vienna, Austria)

15:20  Value of Diamine Oxidase as Novel Marker of Mast Cell Activation
Thomas Böhm & Bernd Jilma (Vienna, Austria)

15:40  STAT5 as Marker and Therapeutic Target in Hematopoietic Neoplasms
Richard Moriggl (Vienna, Austria)

16:00  Establishment of iPSC from Patients with Mast Cell Neoplasms
Mathias Schneeweiß (Vienna, Austria)

16:20  Role of TRKA Receptor in the Etiology of Mastocytosis in Mice and in the
Development of Resistance against KIT-Targeted Therapy
Zhixiong Li (Hannover, Germany)
16:40  Genetic Mouse Models for Evaluating Oncogenesis in Hematopoietic Neoplasms
Mathias Müller (Vienna, Austria)

17:00  Coffee Break

17:30-19:00  Session V: Markers in Human and Canine Mast Cell Neoplasms
Chair: P. Valent and M. Arock

17:30  The Serum Tryptase Test: A Robust Biomarker in Human Mastocytosis
Wolfgang R. Sperr (Vienna, Austria)

17:50  Serum Tryptase Measurements in Canine Mastocytoma
David M. Vail (Madison, WI, USA)

18:10  Diagnostic and Prognostic Value of Aberrant CD2, CD25 and CD30
in Human Mast Cell Neoplasms
Karl Sotlar (Salzburg, Austria)

18:30  Effects of Ibrutinib on Growth and Function of Neoplastic Canine Mast Cells
Susanne Gamperl (Vienna, Austria)

18:50  Summary
Peter Valent